The high efficacy of proton pump inhibitors (PPIs) makes this class of drugs one of the most widely used. PPIs should be considered as basic drugs in the treatment of patients with widespread and socially significant acid-dependent diseases. PPIs are taken by millions of people.
With diseases such as reflux esophagitis, Zollinger-Ellison syndrome, long-term treatment is required – months, years, and sometimes for life.
A new proton pump inhibitor has appeared on the domestic market – the drug Download article in PDF (active ingredient pantoprazole) from the World Medicine company.
ULSEPAN is available in several forms of release: tablets No. 14, No. 28 and lyophilisate for solution preparation, vial No. 1.
ULSEPAN is indicated for the treatment of reflux esophagitis, Zollinger-Ellison syndrome and other hypersecretory conditions, as well as in the complex eradication of H. pylori in patients with gastric and duodenal ulcers.
The convenience of using ULSEPAN is due to the fact that it is possible to switch from the injectable form of the drug to the tablet form and vice versa, depending on the pathology and severity of the disease.
It is possible to regulate the duration of the use of ULSEPAN by choosing the tablet form. So No. 14 is suitable for a short course of treatment with H. pylori eradication as part of complex therapy and for the treatment of duodenal ulcer, and No. 28 is best used for the treatment of gastric ulcer and reflux esophagitis.
The course of treatment will be determined by the doctor, and depending on this, the patient will have a choice in terms of the number of tablets in the package.
Presented on the pharmaceutical market of Ukraine, the drug ULSEPAN is a drug of European quality with an affordable price for the domestic consumer.